Prostate Cancer - Results from #21920

Cabozantinib: A novel agent with a dual mechanism of action for castration-resistant prostate carcinoma - Abstract December 5, 2013

The hurdle of antiandrogen drug resistance: Drug design strategies - Abstract December 5, 2013

Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: Case report - Abstract December 4, 2013

Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer - Abstract December 4, 2013

Methods and rationale used in a matched cohort study of the incidence of new primary cancers following prostate cancer - Abstract December 4, 2013

Prostate cancer tumour features on template prostate-mapping biopsies: Implications for focal therapy - Abstract December 4, 2013

EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013 - Abstract December 4, 2013

Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: Long-term follow-up - Abstract December 4, 2013

Patient-reported outcomes in randomised controlled trials of prostate cancer: Methodological quality and impact on clinical decision making - Abstract December 4, 2013

Return to work and sick leave after radical prostatectomy: A prospective clinical study - Abstract December 3, 2013

Moderately hypofractionated radiotherapy for localized prostate cancer: Long-term outcome using IMRT and volumetric IGRT - Abstract December 3, 2013

Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla - Abstract December 3, 2013

The role of interpersonal relationships in men's attendance in primary care: Qualitative findings in a cohort of men with prostate cancer - Abstract December 3, 2013

Diffusion-weighted imaging of prostate cancer on 3T MR: Relationship between apparent diffusion coefficient values and Ki-67 expression - Abstract December 3, 2013

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer - Abstract December 3, 2013

Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer - Abstract December 3, 2013

Medivation and Astellas initiate phase 3 study of enzalutamide in non-metastatic castration-resistant prostate cancer December 3, 2013

Management of hormone-sensitive metastatic prostate cancer - Abstract December 3, 2013

Management of patients with castration-resistant disease - Abstract December 3, 2013

Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer - Abstract December 3, 2013

Page 1097 of 1447